dc.contributor.author
Burns, Marie
dc.contributor.author
Ostendorf, Lennard
dc.contributor.author
Biesen, Robert
dc.contributor.author
Grützkau, Andreas
dc.contributor.author
Hiepe, Falk
dc.contributor.author
Mei, Henrik E.
dc.contributor.author
Alexander, Tobias
dc.date.accessioned
2021-07-26T15:32:37Z
dc.date.available
2021-07-26T15:32:37Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/31416
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-31149
dc.description.abstract
Given its uniformly high expression on plasma cells, CD38 has been considered as a therapeutic target in patients with systemic lupus erythematosus (SLE). Herein, we investigate the distribution of CD38 expression by peripheral blood leukocyte lineages to evaluate the potential therapeutic effect of CD38-targeting antibodies on these immune cell subsets and to delineate the use of CD38 as a biomarker in SLE. We analyzed the expression of CD38 on peripheral blood leukocyte subsets by flow and mass cytometry in two different cohorts, comprising a total of 56 SLE patients. The CD38 expression levels were subsequently correlated across immune cell lineages and subsets, and with clinical and serologic disease parameters of SLE. Compared to healthy controls (HC), CD38 expression levels in SLE were significantly increased on circulating plasmacytoid dendritic cells, CD14(++)CD16(+) monocytes, CD56(+) CD16(dim) natural killer cells, marginal zone-like IgD(+)CD27(+) B cells, and on CD4(+) and CD8(+) memory T cells. Correlation analyses revealed coordinated CD38 expression between individual innate and memory T cell subsets in SLE but not HC. However, CD38 expression levels were heterogeneous across patients, and no correlation was found between CD38 expression on immune cell subsets and the disease activity index SLEDAI-2K or established serologic and immunological markers of disease activity. In conclusion, we identified widespread changes in CD38 expression on SLE immune cells that highly correlated over different leukocyte subsets within individual patients, but was heterogenous within the population of SLE patients, regardless of disease severity or clinical manifestations. As anti-CD38 treatment is being investigated in SLE, our results may have important implications for the personalized targeting of pathogenic leukocytes by anti-CD38 monoclonal antibodies.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
immune profiling
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
2424
dcterms.bibliographicCitation.doi
10.3390/ijms22052424
dcterms.bibliographicCitation.journaltitle
International Journal of Molecular Sciences
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
MDPI AG
dcterms.bibliographicCitation.volume
22
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33670902
dcterms.isPartOf.eissn
1422-0067